Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein SA pseudogene 22 (RPSAP22) is a processed pseudogene that is part of the *RPSA* gene family, which includes the gene encoding ribosomal protein SA (also known as 37-kDa laminin receptor precursor/67-kDa laminin receptor, LRP/LR)[1][5]. While ribosomal protein SA itself serves as a ribosomal protein as well as a multifunctional receptor involved in cell adhesion, migration, and various pathologies including cancer and prion diseases, the pseudogene RPSAP22 is an inactive genomic sequence that does not encode a functional protein. Most *RPSA* pseudogenes were formed by retropositional events and typically carry mutations (frameshifts, premature stop codons, missing start codons) that prevent them from coding for active proteins[1]. Some RPSA pseudogenes may produce non-coding RNA with potential regulatory functions, though there is no specific evidence for RPSAP22 itself. RPSAP22 is not a druggable or therapeutic target, as it does not produce a functional product or interface with drugs or disease processes.
None. Drugs do not target RPSAP22 as a pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein SA pseudogene 22 (RPSAP22).